The article discusses the continued spread of SARS-CoV-2 despite previous measures such as travel restrictions. However, the implementation of COVID-19 vaccines has led to the recommendation of utilizing 'vaccine passports' to allow for the safe resumption of travel. This solution is deemed temporary and aims to facilitate travel while keeping safety measures in mind.

The development of COVID-19 vaccines has been focused mainly on healthy adults and the elderly, with children being marginally involved in clinical trials. However, the availability of a safe and effective pediatric vaccine is mandatory for clinical and epidemiological reasons, and cooperation among governments, researchers, and pharmaceutical companies is required. Although the development of a pediatric vaccine presents significant challenges, its importance cannot be overstated in the fight against the COVID-19 pandemic. Therefore, urgent efforts must be made to ensure the development and distribution of a safe and effective COVID-19 vaccine for children.

The results of a major clinical trial of the Pfizer-BioNTech coronavirus vaccine have shown it is 95% effective, with a consistent level of protection across all age groups and ethnicities. The vaccine was tested on 43,500 people in six countries, with a 1:1 ratio between the vaccine and a placebo, and was found to offer “complete protection” from severe illness. The Pfizer-BioNTech vaccine is based on experimental technology that uses RNA molecules to trigger an immune response, which could revolutionize the vaccine industry. The efficacy rate puts it on a par with vaccines that have come before, including ones for measles and polio, and it is hoped it can help bring the pandemic under control. The companies plan to apply for emergency authorization from the US Food and Drug Administration within the next few days.

The US government's Operation Warp Speed task force is spending around $10 billion on public-private partnerships to expedite the development, manufacture, and distribution of coronavirus vaccines so that one or more may be approved for emergency use in late 2020 or 2021. However, they face the challenge of convincing hesitant Americans to take the vaccine. US vaccination rates for some infectious diseases have been flat or falling, which has driven resurgent outbreaks, so convincing the public to take a fast-tracked vaccine will be crucial for defeating the pandemic. In an August 2020 Gallup poll, one in three respondents said they planned to forgo an inoculation because of safety concerns, and in September 2020, only 51% of US adults reported that they would definitely or probably get a vaccine to prevent COVID-19, a drop from 72% in May. Creating an effective vaccine is only half the battle; if people refuse to take it, the impact will be limited. Social and behavioral scientists have studied how to improve vaccination rates for decades, and their research sprawls across several disciplines including psychology, communications, public health, medicine, nursing, sociology, and behavioral economics.

A study conducted by the Centers for Disease Control and Prevention (CDC) in the US has found that receiving an mRNA COVID-19 vaccine preconception or during pregnancy is not associated with an increased risk of spontaneous abortion (SAB). Among the 2,456 pregnant people who received the vaccine preconception or prior to 20 weeks’ gestation, the cumulative risk of SAB from 6-19 weeks’ gestation was 14.1%, which is within the expected range of SABs in recognised pregnancies. These findings suggest that mRNA COVID-19 vaccines during pregnancy are safe, and add to the accumulating evidence on their safety. Although there is no compelling biological reason to expect the vaccine to present a risk to pregnancy, there has been ongoing public concern regarding its safety during pregnancy. However, the study found that there was a higher risk of adverse pregnancy outcomes associated with SARS-CoV-2 infection during pregnancy, including severe illness. The study used data from the v-safe pregnancy registry, a voluntary smartphone-based surveillance system, to assess the risk of SAB. The authors of the study hope that these findings will provide further reassurance to pregnant people and healthcare providers, and encourage more pregnant individuals to receive the vaccine.

A study has evaluated instances of adverse effects following immunization (AEFIs) related to the COVID-19 mRNA vaccine, using the Vaccine Adverse Event Reporting System (VAERS) database. The report covered AEFIs that took place in December 2020, where VAERS reported 3,908 AEFIs, with nearly 80% of these identified following the first vaccine dose. The majority of AEFIs were general and nervous system disorders, with gastrointestinal disorders also noted. The research additionally found that a history of allergies was more likely in vaccine recipients that experienced anaphylaxis following the vaccine. In contrast, patients with a history of anxiety or depression had a higher risk of experiencing severe neurological AEFIs. Those who reported death were generally older, had hypertension, and experienced neurological disorders more often than other vaccine recipients. Of the total reported cases, 2.53% required hospitalization, whilst others attended a clinic or emergency room. Despite the higher risk for some groups, the authors concluded that AEFIs related to COVID-19 mRNA vaccines were predominantly non-severe and systemic reactions. Nonetheless, closer monitoring and assessment of vaccine recipients with pre-existing conditions remains necessary.

A new study has developed a safe vaccine platform for preventing COVID-19. The main target for COVID-19 vaccine candidates is the large SARS-CoV-2 spike (S) protein. However, this protein can produce complications or enhancement of COVID-19 disease. In response, the study team developed a safe single round rhabdovirus replicon vaccine platform that creates a chimeric minispike that is less likely to produce complications. The chimeric minispike is a globular RBD linked to a transmembrane stem-anchor sequence derived from rabies virus glycoprotein. The replicons encode the minispike, which stimulates high titers of SARS-CoV-2 neutralizing antibodies and protects transgenic K18-hACE2 mice from COVID-19-like disease. Homologous boost immunisation further enhanced neutralizing activity. These results demonstrate that the non-spreading rhabdovirus RNA replicons expressing minispike proteins represent effective and safe alternatives to vaccination approaches using replication-competent viruses and/or the entire S antigen. This study is important as safety concerns have previously been raised regarding the safety of viral DNA and RNA delivery vectors used in COVID-19 vaccine candidates, and concern over potential side effects caused by the antigen itself.

The timing of vaccine rollout has a significant impact on the decision-making process of individuals regarding COVID-19 vaccines, according to a study published in the journal PLOS ONE. Researchers found that delayed availability is correlated with lower levels of vaccine hesitancy and rejection, indicating that timing is a critical factor in vaccine uptake. The study utilized mixed-methods, including a survey experiment and qualitative data analysis, to better understand the decision-making process of individuals. Findings indicated that temporal expressions, such as a desire to wait, can serve as an indicator of deeper concerns around safety, efficacy, personal situations, or altruism. Understanding these underlying factors can inform better vaccine policies and messaging and enhance overall understanding of how individuals make decisions about vaccines. The study emphasizes the importance of addressing vaccine hesitancy through public health efforts, particularly in terms of demographic and attitudinal correlates, as well as the role of timing in vaccine uptake.

A candidate vaccine for COVID-19 based on a gorilla adenovirus called GRAd-COV2 has been found to be safe and effective in a phase 1, dose-escalation, open-labeled clinical trial. Compared to existing COVID-19 vaccines that use human or closely related chimpanzee adenoviruses, GRAd-COV2 could avoid preexisting antivector immunity. The trial involved 90 healthy participants, aged 18 to 55 years old and 65 to 85 years old, who received a single intramuscular administration of GRAd-COV2 at three escalating doses. Four weeks after vaccination, seroconversion to two SARS-CoV-2 proteins was achieved in all participants, with neutralizing antibodies detected in the majority. The vaccine also induced a robust T cell response. Local and systemic adverse reactions were mostly mild or moderate and of short duration, and no serious adverse events were reported. These results support the further development of GRAd-COV2 as a COVID-19 vaccine. With global vaccine demand still outstripping supply, the development of safe and effective vaccines is crucial to ending the ongoing pandemic.

The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group has evaluated research on the potential risk of immune enhancement of disease by vaccines and viral infections, including coronavirus infections, together with emerging data about COVID-19 disease. They concluded that vaccine-associated enhanced disease has been rarely encountered with existing vaccines or viral infections, and neither principles of immunity nor preclinical studies provide a basis for prioritizing among the COVID-19 vaccine candidates with respect to safety at this time. However, rigorous clinical trial design and postlicensure surveillance are essential to determine the safety of candidate vaccines and to identify adverse events, including the potential for enhanced severity of COVID-19 disease, after vaccination. Animal models of SARS-CoV-2 infection may help elucidate mechanisms of immune protection, but observations of enhanced disease in people receiving candidate COVID-19 vaccines are needed to understand the risk of immune enhancement of disease. In summary, while rapid development of an efficacious vaccine against COVID-19 is essential, safety and risk assessment must remain a top priority in the vaccine development process.